Related Experiment Video
Updated: Apr 1, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
Molecular Magnetic Resonance Imaging of Tumor Response to Therapy
Adam J Shuhendler1,2, Deju Ye1,2, Kimberly D Brewer1,2
1Molecular Imaging Program at Stanford, Stanford, California 94305, USA.
Abstract:
Personalized cancer medicine requires measurement of therapeutic efficacy as early as possible, which is optimally achieved by three-dimensional imaging given the heterogeneity of cancer. Magnetic resonance imaging (MRI) can obtain images of both anatomy and cellular responses, if acquired with a molecular imaging contrast agent. The poor sensitivity of MRI has limited the development of activatable molecular MR contrast agents. To overcome this limitation of molecular MRI, a novel implementation of our caspase-3-sensitive nanoaggregation MRI (C-SNAM) contrast agent is reported. C-SNAM is triggered to self-assemble into nanoparticles in apoptotic tumor cells, and effectively amplifies molecular level changes through nanoaggregation, enhancing tissue retention and spin-lattice relaxivity. At one-tenth the current clinical dose of contrast agent, and following a single imaging session, C-SNAM MRI accurately measured the response of tumors to either metronomic chemotherapy or radiation therapy, where the degree of signal enhancement is prognostic of long-term therapeutic efficacy. Importantly, C-SNAM is inert to immune activation, permitting radiation therapy monitoring.
Insights
This study introduces a novel MRI contrast agent, C-SNAM, that detects cancer treatment effectiveness early. C-SNAM enhances imaging sensitivity, enabling precise monitoring of therapeutic responses in personalized cancer medicine.
Area of Science:
- Biomedical Imaging
- Molecular Imaging
- Nanotechnology
Background:
- Personalized cancer medicine necessitates early therapeutic efficacy assessment.
- Three-dimensional imaging is optimal for heterogeneous tumors.
- Molecular Magnetic Resonance Imaging (MRI) requires sensitive contrast agents for cellular response detection.
Purpose of the Study:
- To develop an activatable molecular MRI contrast agent overcoming sensitivity limitations.
- To report a novel caspase-3-sensitive nanoaggregation MRI (C-SNAM) contrast agent.
- To evaluate C-SNAM's efficacy in measuring early tumor response to therapy.
Main Methods:
- Development of C-SNAM, a contrast agent that self-assembles into nanoparticles in apoptotic tumor cells.
- Utilizing C-SNAM's nanoaggregation to amplify molecular signals and enhance MRI detection.
- Administering C-SNAM at a reduced dose (one-tenth of clinical standard) for imaging tumor response.
Main Results:
- C-SNAM MRI accurately measured tumor response to metronomic chemotherapy and radiation therapy after a single imaging session.
- The degree of signal enhancement correlated with long-term therapeutic efficacy, serving as a prognostic indicator.
- C-SNAM demonstrated inertness to immune activation, allowing for radiation therapy monitoring.
Conclusions:
- C-SNAM offers a highly sensitive method for early measurement of cancer therapeutic efficacy using MRI.
- The agent's nanoaggregation mechanism enhances detection and prognostic value.
- C-SNAM is a promising tool for personalized cancer medicine and monitoring radiation therapy.
More Related Videos
06:44Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
Published on: June 7, 2020
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
